A Phase 2 interventional study of SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 36 sites in 8 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-04-30.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.
Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 34th largest by enrollment, is one of 11 that started in 2014, is one of 31 in phase 2, and was the 26th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:
Eastern Idaho Public Health
Ages 18+
Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 34 · Phase 3 31 · Phase 4 22
First in 2010; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 75 across the 94 interventional studies. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 94 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 52nd largest by enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2014, is one of 47 in phase 2, and was the 53rd registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 94 studies testing sofosbuvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will have two parts as follows:
The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric participants. The PK Lead-in Phase will also evaluate the safety and tolerability of 7 days of dosing of SOF+ribavirin (RBV) in HCV-infected pediatric participants.
The Treatment Phase will be initiated by age cohort after confirmation of age-appropriate SOF dosage levels. Participants from the PK Lead-in Phase will immediately rollover into the Treatment Phase with no interruption of study drug administration. The Treatment Phase will evaluate the antiviral efficacy, safety, and tolerability of SOF+RBV for 12 or 24 weeks in pediatric participants with genotype 2 or 3 HCV infection, respectively.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants between 12 to \< 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
Drug: SOF · Drug: RBV
Participants between 12 to \< 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
Drug: SOF · Drug: RBV
Participants between 6 to \< 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
Drug: SOF · Drug: RBV
Participants between 6 to \< 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and \< 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
Drug: SOF · Drug: RBV
Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
Drug: SOF · Drug: RBV
Participants between 3 to \< 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing \< 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
Drug: SOF · Drug: RBV
For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Time frame: 6 to < 18 years of age: predose, 0.5, 1, 2, 3, 4, 8, and 12 hours postdose on Day 7; 3 to < 6 years of age: predose, 2, 4, 8, and 12 hours postdose on Day 7
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
Time frame: Up to 24 weeks
For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
Time frame: Baseline; Weeks 1, 2, 4, 8, and 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
Time frame: Up to Day 7
For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
Time frame: Posttreatment Week 4
For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
Time frame: Posttreatment Week 24
For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.
Time frame: Up to 24 weeks
For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
Time frame: Up to Posttreatment Week 24
For the Treatment Phase, Change From Baseline in HCV RNA
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only)
For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit. One participant in the 3 to \< 6 Years Old 12 Weeks group had ALT \> ULN at Baseline, but had no other available data.
Time frame: Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Week 4
For the Treatment Phase, Change From Baseline in Height
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
For the Treatment Phase, Change From Baseline in Weight
Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16 (24 Week groups only), 20 (24 Week groups only), and 24 (24 Week groups only), and Posttreatment Weeks 4, 12, and 24
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
Time frame: Baseline; End of Treatment (either Week 12 or 24), Posttreatment Week 12, and Posttreatment Week 24
For the Treatment Phase, Palatability of SOF Granules at Day 1 as Assessed by the Percentage of Participants Able/Unable to Taste the SOF Oral Granules
Participants were asked if they were able to taste the SOF oral granules.
Time frame: Day 1
Participants were enrolled at study sites in Australia, Europe, Russia, New Zealand, and the United States. The first participant was screened on 07 July 2014. The last study visit occurred on 13 September 2018.
| Milestone | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Started | 4 | 6 | 2 | 10 | 4 | 8 |
| Completed | 4 | 6 | 2 | 10 | 4 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Started | 13 | 39 | 13 | 28 | 5 | 8 |
| Completed | 13 | 38 | 13 | 28 | 4 | 8 |
| Not completed | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
| h*ng/mL | PK Lead-in: 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks | PK Lead-in: 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks | PK Lead-in: 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks |
|---|---|---|---|
| For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF) | 9106.0 ± 2601.96 | 7651.2 ± 1723.32 | 10293.7 ± 1860.57 |
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase | 0 | 0 | 0 | 0 | 20.0 | 0 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| percentage of participants | 12 to < 18 Years Old (Total) - SOF+RBV 12 or 24 Weeks | 3 to < 12 Years Old (Total) - SOF+RBV 12 or 24 Weeks | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12) | 98.1 (89.7 to 100.0) | 98.1 (90.1 to 100.0) | 100.0 (75.3 to 100.0) | 97.4 (86.5 to 99.9) | 100.0 (75.3 to 100.0) | 100.0 (87.7 to 100.0) | 80.0 (28.4 to 99.5) | 100.0 (63.1 to 100.0) |
| log10 IU/mL | PK Lead-in: 12 to < 18 Years Old - SOF+RBV 12 Weeks | PK Lead-in: 12 to < 18 Years Old - SOF+RBV 24 Weeks | PK Lead-in: 6 to < 12 Years Old - SOF+RBV 12 Weeks | PK Lead-in: 6 to < 12 Years Old - SOF+RBV 24 Weeks | PK Lead-in: 3 to < 6 Years Old - SOF+RBV 12 Weeks | PK Lead-in: 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Change at Week 1 | -3.98 ± 1.056 | -4.23 ± 0.765 | -3.82 ± 0.447 | -3.78 ± 1.234 | -4.12 ± 0.632 | -3.53 ± 0.347 |
| Change at Week 2 | -4.84 ± 0.743 | -4.34 ± 0.758 | -4.92 ± 0.674 | -4.56 ± 1.553 | -4.31 ± 0.846 | -3.94 ± 0.422 |
| Change at Week 4 | -4.84 ± 0.743 | -4.34 ± 0.758 | -4.92 ± 0.674 | -4.60 ± 1.686 | -4.42 ± 1.006 | -3.97 ± 0.453 |
| Change at Week 8 | -4.84 ± 0.743 | -4.34 ± 0.758 | -4.92 ± 0.674 | -4.61 ± 1.700 | -4.52 ± 1.177 | -3.97 ± 0.453 |
| Change at Week 12 | -4.84 ± 0.743 | -4.34 ± 0.758 | -4.92 ± 0.674 | -4.61 ± 1.700 | -4.52 ± 1.177 | -3.97 ± 0.453 |
| Change at Week 16 | — | -4.34 ± 0.758 | — | -4.61 ± 1.700 | — | -3.97 ± 0.453 |
| Change at Week 20 | — | -4.34 ± 0.758 | — | -4.61 ± 1.700 | — | -3.97 ± 0.453 |
| Change at Week 24 | — | -4.34 ± 0.758 | — | -4.61 ± 1.700 | — | -3.97 ± 0.453 |
| percentage of participants | PK Lead-in: 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks | PK Lead-in: 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks | PK Lead-in: 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks |
|---|---|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase | 0 | 0 | 0 |
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4) | 100.0 (75.3 to 100.0) | 100.0 (91.0 to 100.0) | 100.0 (75.3 to 100.0) | 100.0 (87.7 to 100.0) | 80.0 (28.4 to 99.5) | 100.0 (63.1 to 100.0) |
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24) | 100.0 (75.3 to 100.0) | 97.4 (86.5 to 99.9) | 100.0 (75.3 to 100.0) | 100.0 (87.7 to 100.0) | 80.0 (28.4 to 99.5) | 100.0 (63.1 to 100.0) |
Viral breakthrough was defined as having confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment.
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough | 0 | 0 | 0 | 0 | 0 | 0 |
Viral relapse was defined as having confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse | 0 | 0 | 0 | 0 | 0 | 0 |
| log10 IU/mL | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Change at Week 1 | -4.25 ± 0.986 | -4.12 ± 0.733 | -4.12 ± 0.692 | -3.88 ± 0.928 | -4.12 ± 0.632 | -3.53 ± 0.347 |
| Change at Week 2 | -4.74 ± 0.980 | -4.86 ± 0.702 | -4.55 ± 0.812 | -4.51 ± 1.102 | -4.31 ± 0.846 | -3.94 ± 0.422 |
| Change at Week 4 | -4.74 ± 0.980 | -5.01 ± 0.760 | -4.68 ± 0.843 | -4.56 ± 1.171 | -4.42 ± 1.006 | -3.97 ± 0.453 |
| Change at Week 8 | -4.74 ± 0.980 | -5.02 ± 0.771 | -4.68 ± 0.843 | -4.54 ± 1.191 | -4.52 ± 1.177 | -3.97 ± 0.453 |
| Change at Week 12 | -4.74 ± 0.980 | -5.02 ± 0.771 | -4.68 ± 0.843 | -4.57 ± 1.178 | -4.52 ± 1.177 | -3.97 ± 0.453 |
| Change at Week 16 | — | -5.02 ± 0.771 | — | -4.57 ± 1.178 | — | -3.97 ± 0.453 |
| Change at Week 20 | — | -5.02 ± 0.771 | — | -4.57 ± 1.178 | — | -3.97 ± 0.453 |
| Change at Week 24 | — | -5.02 ± 0.771 | — | -4.57 ± 1.178 | — | -3.97 ± 0.453 |
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Week 1 | 30.8 (9.1 to 61.4) | 30.8 (17.0 to 47.6) | 46.2 (19.2 to 74.9) | 39.3 (21.5 to 59.4) | 50.0 (6.8 to 93.2) | 37.5 (8.5 to 75.5) |
| Week 2 | 100.0 (75.3 to 100.0) | 74.4 (57.9 to 87.0) | 76.9 (46.2 to 95.0) | 78.6 (59.0 to 91.7) | 75.0 (19.4 to 99.4) | 87.5 (47.3 to 99.7) |
| Week 4 | 100.0 (75.3 to 100.0) | 92.3 (79.1 to 98.4) | 100.0 (75.3 to 100.0) | 96.4 (81.7 to 99.9) | 75.0 (19.4 to 99.4) | 100.0 (63.1 to 100.0) |
| Week 8 | 100.0 (75.3 to 100.0) | 100.0 (91.0 to 100.0) | 100.0 (75.3 to 100.0) | 96.4 (81.7 to 99.9) | 100.0 (39.8 to 100.0) | 100.0 (63.1 to 100.0) |
| Week 12 | 100.0 (75.3 to 100.0) | 100.0 (91.0 to 100.0) | 100.0 (75.3 to 100.0) | 100.0 (87.7 to 100.0) | 100.0 (39.8 to 100.0) | 100.0 (63.1 to 100.0) |
| Week 16 | — | 100.0 (91.0 to 100.0) | — | 100.0 (87.7 to 100.0) | — | 100.0 (63.1 to 100.0) |
| Week 20 | — | 100.0 (91.0 to 100.0) | — | 100.0 (87.7 to 100.0) | — | 100.0 (63.1 to 100.0) |
| Week 24 | — | 100.0 (91.0 to 100.0) | — | 100.0 (87.7 to 100.0) | — | 100.0 (63.1 to 100.0) |
ALT normalization was defined as ALT \> the upper limit of normal (ULN) at baseline and ALT ≤ ULN at each visit. One participant in the 3 to \< 6 Years Old 12 Weeks group had ALT \> ULN at Baseline, but had no other available data.
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Week 1 | 50.0 | 63.6 | 25.0 | 75.0 | — | 100.0 |
| Week 2 | 100.0 | 90.9 | 100.0 | 93.3 | — | 100.0 |
| Week 4 | 100.0 | 95.5 | 100.0 | 100.0 | — | 100.0 |
| Week 8 | 100.0 | 95.5 | 100.0 | 100.0 | — | 100.0 |
| Week 12 | 100.0 | 100.0 | 100.0 | 100.0 | — | 100.0 |
| Week 16 | — | 100.0 | — | 100.0 | — | 100.0 |
| Week 20 | — | 100.0 | — | 100.0 | — | 100.0 |
| Week 24 | — | 100.0 | — | 100.0 | — | 100.0 |
| Posttreatment Week 4 | 100.0 | 100.0 | 100.0 | 100.0 | — | 100.0 |
| centimeters | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Change at Week 1 | 0.1 ± 1.10 | 0.0 ± 0.57 | 0.0 ± 0.57 | 0.0 ± 0.73 | 0.3 ± 1.12 | 0.3 ± 0.75 |
| Change at Week 2 | 0.1 ± 1.07 | -0.1 ± 0.59 | 0.1 ± 0.66 | 0.0 ± 0.54 | 0.7 ± 1.09 | 0.3 ± 0.50 |
| Change at Week 4 | 0.2 ± 1.20 | 0.2 ± 0.78 | 0.3 ± 0.67 | 0.4 ± 0.74 | 0.9 ± 0.87 | 0.5 ± 0.67 |
| Change at Week 8 | 0.3 ± 1.27 | 0.2 ± 0.85 | 1.0 ± 1.00 | 0.4 ± 0.62 | 0.9 ± 0.72 | 0.8 ± 0.51 |
| Change at Week 12 | 0.5 ± 1.68 | 0.3 ± 0.95 | 0.8 ± 0.81 | 0.7 ± 0.68 | 1.5 ± 0.45 | 1.7 ± 1.84 |
| Change at Week 16 | — | 0.4 ± 0.91 | — | 1.1 ± 0.93 | — | 1.8 ± 0.79 |
| Change at Week 20 | — | 0.5 ± 1.10 | — | 1.6 ± 1.15 | — | 2.5 ± 1.01 |
| Change at Week 24 | — | 0.8 ± 1.54 | — | 2.1 ± 0.88 | — | 2.7 ± 1.05 |
| Change at Posttreatment Week 4 | 0.5 ± 1.79 | 0.9 ± 1.70 | 1.4 ± 0.80 | 2.6 ± 1.17 | 1.6 ± 0.91 | 3.5 ± 0.85 |
| Change at Posttreatment Week 12 | 1.4 ± 1.65 | 1.3 ± 1.90 | 2.4 ± 1.02 | 3.8 ± 1.30 | 2.8 ± 1.81 | 4.0 ± 0.95 |
| Change at Posttreatment Week 24 | 1.6 ± 1.89 | 1.8 ± 2.83 | 4.2 ± 1.11 | 5.1 ± 1.59 | 5.0 ± 1.61 | 5.7 ± 1.27 |
| kilograms | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Change at Week 1 | -0.7 ± 1.28 | -0.4 ± 1.36 | 0.2 ± 0.82 | 0.0 ± 0.55 | 0.2 ± 0.10 | -0.2 ± 0.51 |
| Change at Week 2 | -0.2 ± 0.87 | -0.3 ± 0.99 | 0.3 ± 1.08 | 0.0 ± 0.64 | 0.5 ± 0.21 | -0.1 ± 0.50 |
| Change at Week 4 | -0.2 ± 1.67 | -0.1 ± 1.15 | 0.4 ± 0.90 | 0.1 ± 0.90 | 0.0 ± 0.22 | -0.1 ± 0.49 |
| Change at Week 8 | -0.5 ± 2.39 | 0.0 ± 1.53 | 0.6 ± 1.57 | 0.1 ± 1.21 | 0.3 ± 0.14 | 0.0 ± 0.55 |
| Change at Week 12 | -0.4 ± 2.62 | -0.1 ± 2.01 | 0.9 ± 2.15 | 0.5 ± 1.35 | 0.3 ± 0.22 | 0.1 ± 0.85 |
| Change at Week 16 | — | 0.2 ± 2.35 | — | 0.6 ± 1.34 | — | 0.1 ± 0.76 |
| Change at Week 20 | — | 0.1 ± 2.65 | — | 0.9 ± 1.59 | — | 0.4 ± 0.86 |
| Change at Week 24 | — | 0.5 ± 3.13 | — | 1.2 ± 1.91 | — | 0.4 ± 1.03 |
| Change at Posttreatment Week 4 | -0.3 ± 3.19 | 0.9 ± 3.24 | 1.2 ± 2.20 | 1.3 ± 2.19 | 0.5 ± 0.27 | 0.7 ± 1.05 |
| Change at Posttreatment Week 12 | 0.9 ± 2.69 | 2.1 ± 3.73 | 2.1 ± 3.28 | 2.2 ± 2.21 | 1.0 ± 0.88 | 0.9 ± 1.12 |
| Change at Posttreatment Week 24 | 2.5 ± 4.98 | 3.0 ± 4.62 | 3.8 ± 3.67 | 3.5 ± 2.42 | 1.3 ± 1.10 | 1.7 ± 1.28 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 23 | 10 | 3 |
| End of Treatment — Increase | 8 | 1 | 0 |
| End of Treatment — Decrease | 0 | 0 | 0 |
| Posttreatment Week 12 — No Change | 20 | 9 | 3 |
| Posttreatment Week 12 — Increase | 10 | 2 | 0 |
| Posttreatment Week 12 — Decrease | 0 | 0 | 0 |
| Posttreatment Week 24 — No Change | 20 | 9 | 3 |
| Posttreatment Week 24 — Increase | 11 | 2 | 0 |
| Posttreatment Week 24 — Decrease | 0 | 0 | 0 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 24 | 11 | 3 |
| End of Treatment — Increase | 7 | 0 | 0 |
| End of Treatment — Decrease | 0 | 0 | 0 |
| Posttreatment Week 12 — No Change | 21 | 10 | 3 |
| Posttreatment Week 12 — Increase | 9 | 1 | 0 |
| Posttreatment Week 12 — Decrease | 0 | 0 | 0 |
| Posttreatment Week 24 — No Change | 20 | 9 | 3 |
| Posttreatment Week 24 — Increase | 11 | 2 | 0 |
| Posttreatment Week 24 — Decrease | 0 | 0 | 0 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 20 | 24 | 8 |
| End of Treatment — Increase | 1 | 6 | 0 |
| End of Treatment — Decrease | 0 | 0 | 0 |
| Posttreatment Week 12 — No Change | 18 | 23 | 8 |
| Posttreatment Week 12 — Increase | 2 | 6 | 0 |
| Posttreatment Week 12 — Decrease | 0 | 0 | 0 |
| Posttreatment Week 24 — No Change | 18 | 22 | 8 |
| Posttreatment Week 24 — Increase | 2 | 8 | 0 |
| Posttreatment Week 24 — Decrease | 0 | 0 | 0 |
Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Any shifts (increase or decrease) in Tanner Stage from Baseline were analyzed and presented.
| Participants | 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks |
|---|---|---|---|
| End of Treatment — No Change | 20 | 24 | 8 |
| End of Treatment — Increase | 1 | 5 | 0 |
| End of Treatment — Decrease | 0 | 1 | 0 |
| Posttreatment Week 12 — No Change | 17 | 24 | 8 |
| Posttreatment Week 12 — Increase | 3 | 5 | 0 |
| Posttreatment Week 12 — Decrease | 0 | 0 | 0 |
| Posttreatment Week 24 — No Change | 16 | 19 | 8 |
| Posttreatment Week 24 — Increase | 4 | 11 | 0 |
| Posttreatment Week 24 — Decrease | 0 | 0 | 0 |
Participants were asked if they were able to taste the SOF oral granules.
| percentage of participants | 12 to < 18 Years Old - SOF+RBV 12 or 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 or 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 or 24 Weeks |
|---|---|---|---|
| Able to Taste SOF Granules: Yes | 0 | 42.9 | 75.0 |
| Able to Taste SOF Granules: No | 100.0 | 57.1 | 25.0 |
Collected over Adverse Events (AEs): First dose date up to Week 12 or 24 (depending on group) plus 30 days (includes AEs occurring during the PK Lead-in Phase); All-Cause Mortality: Up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12 to < 18 Years Old - SOF+RBV 12 Weeks | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| 12 to < 18 Years Old - SOF+RBV 24 Weeks | 0/39 (0%) | 0/39 (0%) | 27/39 (69.2%) |
| 6 to < 12 Years Old - SOF+RBV 12 Weeks | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| 6 to < 12 Years Old - SOF+RBV 24 Weeks | 0/28 (0%) | 0/28 (0%) | 24/28 (85.7%) |
| 3 to < 6 Years Old - SOF+RBV 12 Weeks | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| 3 to < 6 Years Old - SOF+RBV 24 Weeks | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Event | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 0/13 | 0/39 | 0/13 | 0/28 | 0/5 | 1/8 |
| Event | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks |
|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/13 | 3/39 | 2/13 | 11/28 | 3/5 | 3/8 |
| DiarrhoeaGastrointestinal disorders | 2/13 | 1/39 | 1/13 | 3/28 | 2/5 | 3/8 |
| Decreased appetiteMetabolism and nutrition disorders | 1/13 | 2/39 | 2/13 | 2/28 | 0/5 | 3/8 |
| HeadacheNervous system disorders | 3/13 | 9/39 | 4/13 | 8/28 | 0/5 | 0/8 |
| NauseaGastrointestinal disorders | 3/13 | 11/39 | 0/13 | 4/28 | 0/5 | 1/8 |
| Arthropod biteInjury, poisoning and procedural complications | 0/13 | 0/39 | 0/13 | 0/28 | 0/5 | 2/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/13 | 3/39 | 1/13 | 7/28 | 1/5 | 0/8 |
| FatigueGeneral disorders | 0/13 | 4/39 | 3/13 | 5/28 | 1/5 | 1/8 |
| Abdominal pain upperGastrointestinal disorders | 2/13 | 2/39 | 1/13 | 0/28 | 1/5 | 0/8 |
| PyrexiaGeneral disorders | 0/13 | 0/39 | 0/13 | 4/28 | 1/5 | 0/8 |
Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks | Total |
|---|---|---|---|---|---|---|---|
| Mean | 15 ± 1.9 | 15 ± 1.9 | 8 ± 2.1 | 9 ± 1.7 | 4 ± 0.8 | 5 ± 0.8 | 11 ± 4.2 |
| Sex: Female, Male(Participants) | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 16 | 10 | 20 | 4 | 6 | 61 |
| Male | 8 | 23 | 3 | 8 | 1 | 2 | 45 |
| Ethnicity (NIH/OMB)(Participants) | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 4 | 1 | 0 | 9 |
| Not Hispanic or Latino | 13 | 36 | 11 | 23 | 4 | 8 | 95 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks | Total |
|---|---|---|---|---|---|---|---|
| Race — White | 11 | 36 | 9 | 20 | 3 | 6 | 85 |
| Race — Asian | 0 | 1 | 2 | 6 | 0 | 1 | 10 |
| Race — Other | 0 | 1 | 2 | 2 | 1 | 1 | 7 |
| Race — Black or African American | 2 | 0 | 0 | 0 | 1 | 0 | 3 |
| Race — Native Hawaiian or Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks | Total |
|---|---|---|---|---|---|---|---|
| New Zealand | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Belgium | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| United States | 8 | 11 | 8 | 10 | 4 | 5 | 46 |
| Italy | 3 | 4 | 2 | 1 | 0 | 1 | 11 |
| United Kingdom | 0 | 2 | 1 | 7 | 1 | 1 | 12 |
| Australia | 0 | 2 | 1 | 5 | 0 | 1 | 9 |
| Germany | 0 | 4 | 0 | 3 | 0 | 0 | 7 |
| Russia | 2 | 15 | 0 | 0 | 0 | 0 | 17 |
| HCV RNA Category(Participants) | 12 to < 18 Years Old - SOF+RBV 12 Weeks | 12 to < 18 Years Old - SOF+RBV 24 Weeks | 6 to < 12 Years Old - SOF+RBV 12 Weeks | 6 to < 12 Years Old - SOF+RBV 24 Weeks | 3 to < 6 Years Old - SOF+RBV 12 Weeks | 3 to < 6 Years Old - SOF+RBV 24 Weeks | Total |
|---|---|---|---|---|---|---|---|
| < 800,000 IU/mL | 5 | 13 | 7 | 15 | 2 | 8 | 50 |
| ≥ 800,000 IU/mL | 8 | 26 | 6 | 13 | 3 | 0 | 56 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2014 to primary completion in Jun 2018, 47 months.
Results were first posted in Apr 2019, 10 months after primary completion.
Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 47 months is above that.
Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Ribavirin